Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Adaptimmune ‘Neck And Neck’ For First Solid Tumor T-Cell Therapy Nod For Afami-Cel

Company Looks Beyond Small Sarcoma Market For Afamitresgene Autoleucel

Executive Summary

The company’s CEO and chief medical officer talked about some challenges as well as opportunities and what they have learned from the experience of other cell therapies.

You may also be interested in...



ASCO: Presentations Showcase Possibilities Of Next-Generation Cell Therapies

An education session looked at ways researchers are hoping to make cell therapies more applicable in solid tumors.

Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: a preview of the ASCO meeting; small biopharma companies thrive in the US; the world’s first positive Phase III data for a microbiome therapy; Adaptimmune’s plans for its T-cell receptor therapy; and Novo looks at semaglutide in early Alzheimer’s.

CEO Exit Adds To Iovance Woes After Cell Therapy Setback

Iovance has a promising new cancer cell therapy on its hands, but another FDA query and the CEO’s departure has spooked investors.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144399

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel